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Abstract (248 words) 
 
Recent data suggest that myocardial septal late gadolinium enhancement (LGE) may have 
an independent prognostic value in patients with acute myocarditis undergoing cardiac 
magnetic resonance (CMR). Aim of the present paper is to evaluate its prevalence and 
prognostic implications in these patients with or without preserved LV function. 
Retrospective cohort study including all cases of clinically suspected acute myocarditis 
referred for CMR. A diagnosis of acute myocarditis was confirmed by CMR according to 
Lake Louise Criteria. Cardiovascular mortality, heart failure, heart transplantation, and 
sustained ventricular arrhythmias were considered adverse events at follow-up.  
Seventy-one patients were included in the present study (mean age 47 years 95% CI 42-
51, 53 males; 75%). LVEF was preserved in 45 cases (63%) and pericardial effusion was 
detected in 26 cases (38%). CMR was performed at a mean time of 11 days (95% CI 7.5-
14.4) from symptoms onset. Myocardial hyperemia and edema was detected in 53 cases 
(75%), myocardial LGE in 66 cases (93%). Septal LGE was reported in 21 cases (30%). 
After a mean follow-up of 60.8 months, the mean LVEF increased from 51.6±14.0% to 
56.6±10.9% (p=0.021) and combined adverse events were only recorded in 4 patients 
(6%) with reduced basal LVEF. These patients had more commonly septal LGE 
(respectively 58%vs.13%,p<0.0001). However, on multivariable analysis septal LGE had 
no additional predictive value over reduced basal LVEF.  
In conclusion our study suggests that septal LGE is not uncommon in patients with acute 
myocarditis but has no added prognostic value over reduced LVEF at presentation. 
 
Key words: myocarditis; cardiac magnetic resonance; late gadolinium enhancement  
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In clinical practice, acute myocarditis has a spectrum of clinical presentation ranging 
from asymptomatic, infarct-like, arrhythmic course, heart failure, to sudden cardiac 
death.1 Infarct-like presentations with preserved LV function seem to have the best 
outcomes without mortality and evolving LV dysfunction.2,3 Cardiac magnetic 
resonance (CMR) is a well-established imaging tool for the non-invasive diagnosis of 
acute myocarditis providing evidence of myocardial hyperemia, edema and fibrosis.4,5 
In this setting, myocardial late gadolinium enhancement (LGE) may have prognostic 
implications.2,3,6,7 Recent data have been published showing that septal LGE may be 
associated with a worse prognosis regardless of basal LVEF.8 Aim of the present paper 
is to evaluate the prevalence and prognostic implications of septal LGE in unselected 
patients with acute myocarditis with or without preserved LV function. 
 
Methods 
  Retrospective cohort study including all cases of clinically suspected acute 
myocarditis referred for CMR from January 2010 to June 2016 in our center (referral 
center for myopericardial diseases in Torino, Italy). All patients were evaluated by 
echocardiography and CMR. In cases with an initial suspicion of an acute coronary 
syndrome, coronary angiography was performed before additional assessments. CMR 
studies were performed with a 1.5 Tesla GE scan. 
A diagnosis of acute myocarditis was confirmed by CMR according to Lake Louise 
Criteria with presence of at least 2 of 3 CMR criteria including: (1) myocardial 
hyperemia, (2) myocardial edema in STIR-T2-weighted imaging, and (3) myocardial 
LGE.9 
  Baseline data were recorded including type of presentation, markers of inflammation 
and myocardial lesion, LV function, and CMR data. The following events were 
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considered as adverse events during follow-up: cardiovascular mortality, heart failure, 
heart transplantation, and sustained ventricular arrhythmias. 
  A structured clinical follow-up was performed at 6 months and then every year. 
Continuous data are reported as mean and 95% CI. Patients subgroups were 
compared by use of the t test for continuous variables and Fisher’s exact test for 
categorical variables as appropriate. Time to event distributions were estimated with 
the Kaplan-Meier method and compared by use of the log-rank test. A value of p<0.05 
was considered to show statistical significance. Analyses were performed by MedCalc 
Statistical Software version 18 (MedCalc Software bvba, Ostend, Belgium; 
http://www.medcalc.org; 2018). 
 
Results 
  Seventy-one patients were eligible to be included in the present study. The mean age 
was 47 years (95% CI 42-51), with 53 males (75%). The following clinical presentations 
were recorded: infarct-like in 47 cases (66%), heart failure in 18 cases (25%), 
sustained arrhythmias in 6 cases (9%), with 1 case as resuscitated sudden cardiac 
death due to ventricular fibrillation during exertion (1%). LVEF was preserved in 45 
cases (63%) and pericardial effusion was detected in 26 cases (38%) on basal 
echocardiography. 
  CMR was performed at a mean time of 11 days (95% CI 7.5-14.4) from symptoms 
onset. Myocardial hyperemia and edema were detected in 53 cases (74%), myocardial 
LGE in 66 cases (93%). Septal LGE was found in 21 cases (30%), while lateral LGE 
was detected in 58 cases (83%) (Figure 1). 
Data on relevant medical therapy according to basal LVEF are reported in table 1. After 
a mean follow-up of 60.8 months (95% CI 55.9-65.6), the overall mean LVEF increased 
from 51.6 ± 14.0% to 56.6 ± 10.9% (p=0.021; Figure 2) and adverse events were 3 
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cases of heart failure (4%), and 1 case of sustained ventricular arrhythmia terminated 
by an ICD (1%). All adverse events were recorded in patients with reduced basal 
LVEF, but only 2 of them had also septal LGE (Table 1 and 2). Table 1 summarizes the 
main clinical features of patients with and without reduced LVEF at presentation, while 
table 2 summarizes main clinical features in patients with and without septal LGE. 
Patients with a reduced basal LVEF, but not only septal LGE, has a worse event-free 
survival compared with those with a preserved LVEF at presentation (see Figure 3 and 
4). The presence of septal LGE is more common in patients with a reduced baseline 
LVEF: respectively in 15/26 (58%) vs. 6/45 (13%, p<0.0001; see also table 1). 
However, on multivariable analysis (including age, gender, clinical presentation, 
LVEF<50% and septal LGE), it has no additional predictive value over reduced basal 
LVEF.  
 
Discussion 
  The main findings of this study are that overall event rate is low after acute 
myocarditis and is restricted to those with reduced LVEF at baseline (LVEF<50%). 
Infarct-like presentation is the most common type of presentation in acute myocarditis 
and is associated with preserved LVEF and good prognosis without adverse events. 
Adverse events are confined to patients with a non-infarct like presentation (e.g. heart 
failure and sustained arrhythmias) and reduced LVEF. Myocardial septal LGE is more 
common in patients with reduced LVEF but is not an independent prognostic marker in 
these patients. This study supports the concept that reduced LVEF at baseline is the 
major prognostic determinant in such patients. 
Previous studies on patients with acute myocarditis have demonstrated that major 
types of clinical presentations in myocarditis include infarct-like myocarditis, heart 
failure and sustained arrhythmias. Preserved LVEF is usually associated with infarct-
 6 
like myocarditis, and the cardiac transplantation (tx) free-survival is better in such 
patients with no need for cardiac tx compared with patients with myocarditis and 
arrhythmias, who have an intermediate prognosis and patients with heart failure, who 
have the worst prognosis.2,3 A recent Italian study has retrospectively evaluated 386 
patients with acute myocarditis and preserved LVEF.8 A clinical combined endpoint of 
cardiac death, appropriate implantable cardioverter-defibrillator firing, resuscitated 
cardiac arrest, and hospitalization for heart failure was considered. Septal LGE was 
recorded in 135 cases (36%) and was associated with a worse prognosis also in 
patients with preserved LV function. After a mean follow-up of 52 months, the authors 
reported 4 cases of SCD, 2 cases with appropriate ICD shocks and 15 hospitalizations 
for heart failure in patients with septal LGE.8 The study had a retrospective design and 
we suppose that it is possible that some patients with dilated cardiomyopathy (DCM) 
and myocarditis were included. In the setting of DC, septal LGE has a well-established 
negative prognostic meaning. In agreement with other Italian studies,2,3 our study 
confirms that patients with preserved LVEF have a good overall prognosis without SCD 
and need for ICD implantation after a mean follow-up of 60.8 months. In our study, 
septal LGE is associated with lower LVEF and greater LVEDVi but does not seem to 
be an independent prognostic marker from reduced LVEF. 
  We acknowledge possible study limitations related to the limited sample size, the 
selection of relatively stable group of patients able to perform a CMR study and the 
retrospective design. However also in previous studies, the design was retrospective 
and only stable patients able to perform CMR were selected. The strength of this paper 
is that represent a real life study of non-selected patients with acute myocarditis 
undergoing a CMR study within 2 weeks from symptoms onset and with or without 
reduced LVEF. 
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  In conclusion, septal LGE is not uncommon in patients with acute myocarditis and 
reduced LVEF performing a CMR study, but does not seem to have an independent 
prognostic value compared with reduced LVEF. Most patients have an infarct-like 
presentation with preserved LVEF and a good prognosis without SCD, heart failure and 
need for cardiac tx or ICD implantation. The worse prognosis is confined in patients 
with reduced LVEF at presentation. However, it should be remarked that LVEF 
generally improves in those patients and that stable patients who are able to perform a 
CMR study have a low event rate even at long term follow-up. 
 
Disclosures: None 
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Figures legends 
 
Figure 1. Examples of septal and lateral myocardial LGE in patients with acute 
myocarditis. 
Figure 2. Comparison of baseline and final LVEF at the end of follow-up for each 
patient. 
Figure 3. Event-free survival in patients with or without reduced LVEF (LVEF <50%). 
Figure 4. Event-free survival of patients with or without septal LGE. 
 
 
Table 1. Comparison of main clinical features and follow-up data of patients with and 
without preserved LVEF at baseline. 
Variable LVEF  
<50% 
(n= 26) 
≥50% 
(n= 45) 
p value 
Age (years) 53.3 (46.5-60.2) 53.3 (46.5-60.2) 0.999 
Male  21 (84%) 32 (70%) 0.256 
Clinical presentation: 
(1) Infarct-like 
(2) Non-infarct-like 
 
 
10 (39%) 
16 (62%) 
 
 
37 (82%) 
8 (18%) 
 
 
0.0003 
Hs-troponin T (µg/L) 0.66 (0.13-1.20) 0.71 (0.40-1.04) 0.853 
C-reactive protein 
(mg/L) 
70.6 (33.9-107.3) 40.2 (26.5-53.8) 0.057 
Pericardial effusion 6 (23%) 20 (44%) 0.190 
LVEF (%) 36.4 (32.3-40.5) 60.4 (58.9-62.0) <0.0001 
LVEDVi* (ml/m2) 226.4 (201.0-251.8) 158.1 (147.8-168.4) <0.001 
LGE (%) 25 (96%) 41 (91%) 0.646 
Number of involved LV 
segments 
3.2 (1.7-4.7) 3.7 (2.9-4.5) 0.857 
Septal LGE 15 (58%) 6 (13%) <0.0001 
Use of betablockers 
Use of ACEi/ ARB 
Use of antiarrhythmics 
 IC 
 Sotalol 
 Amiodarone 
26 (100%) 
22 (85%) 
2 (8%) 
1 (4%) 
0 
1 (4%) 
34 (76%) 
26 (58%) 
4 (9%) 
1 (2%) 
2 (4%) 
1 (2%) 
0.0106 
0.0198 
0.8859 
0.6210 
0.4713 
0.6210 
Follow-up (months) 60.2 (52.4-68.0) 61.2 (54.8-67.6) 0.844 
Combined adverse 
events* 
(1) CV mortality 
(2) Heart Failure 
(3) Cardiac Tx 
4 (15%) 
 
0 
3 (12%) 
0 
0 
 
0 
0 
0 
0.015 
Table 1
(4) Arrhythmias° 1 (4%) 0 
ACEi= ACE inhibitors/ ARB= Angiotensin II Receptor Blockers; *= cardiovascular mortality 
+ heart failure + cardiac transplantation + sustained ventricular arrhythmias; °= sustained 
ventricular arrhythmias. 
 
Table 2. Comparison of main clinical features and follow-up data of patients with or without 
myocardial septal LGE at baseline. 
Variable Septal LGE  
Yes 
(n= 21) 
No 
(n= 50) 
p value 
Age (years) 56.2 (48.6-63.8) 43.2 (38.2-48.2) 0.0053 
Male  17 (81%) 36 (72%) 0.556 
Clinical 
presentation: 
(1) Infarct-like 
(2) Other 
 
 
10 (48%) 
11 (52%) 
 
 
38 (76%) 
12 (24%) 
 
0.0273 
Hs-troponin T (µg/L) 0.70 (0.17-1.22) 0.70 (0.37-1.03) 0.987 
C-reactive protein 
(mg/L) 
72.5 (34.0-111.0) 41.4 (26.6-56.2) 0.061 
Pericardial effusion 8 18 0.999 
LVEF (%) 39.6 (33.1-46.1) 57.0 (54.0-60.0) <0.0001 
LVEF<50% 15 10 <0.0001 
LVEDVi* (ml/m2) 215.6 (181.8-249.0) 169.7 (157.8-181.6.0) 0.0015 
LGE (%) 21 45 0.312 
Number of involved 
LV segments 
3.1 (1.9-4.3) 3.7 (2.8-4.6) 0.474 
Follow-up (months) 64.6 (55.0-74.2) 59.2 (53.5-64.9) 0.306 
Combined adverse 
events* 
(3) CV mortality 
(4) Heart Failure 
(5) Cardiac Tx 
(6) Arrhythmias 
2 (10%) 
 
0 
2 (10%) 
0 
0 
2 (4%) 
 
0 
1 (2%) 
0 
1 (2%) 
0.576 
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